[Paradigm shift in understanding hyaluronic acid filler effects].
Wollina U., Goldman A.
Narrative Review, published in Hautarzt (2021) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Hautarzt (2021)
- Country
- Germany
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 33660025
- DOI
- 10.1007/s00105-021-04780-x
Abstract (original English)
Hyaluronic acid (hyaluron; HA) is an important constituent of the extracellular matrix and has an age-dependent decrease in tissue concentration. While natural HA is rapidly degraded, filler cross-linked HA achieve a half-life of 6-12 months. Such fillers enjoy increasing popularity in esthetic medicine and are versatile tools. Although HA fillers can activate fibroblasts it is of minor importance for long-term results. Fillers are injected into subcutaneous adipose tissue. Their interaction with somatic stem cells and mature adipocytes has gained increasing interest. Cross-linked HA can indeed support proliferation of pre-adipocytes, stimulate their differentiation into mature adipocytes and protect the mature cells from senescence, apoptosis and lipolysis. This view offers a new perspective on the development of future fillers for esthetic medicine. Hyaluronsäure (Hyaluron; HA) ist eine wichtige Komponente der extrazellulären Matrix, die einen altersabhängigen Konzentrationsabfall zeigt. Während unvernetzte HA rasch abgebaut wird, zeigen Filler mit vernetzter HA Halbwertszeiten von 6 bis 12 Monaten. Diese Filler erfreuen sich zunehmender Beliebtheit in der ästhetischen Medizin und erlauben einen vielfältigen Einsatz. Obwohl HA-Filler Fibroblasten aktivieren können, ist dies für die langfristigen Effekte von untergeordneter Relevanz. Durch die Platzierung der Filler im subkuta
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.